GSK1325756,
N-(4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)phenyl)-N'-(3-fluoro-2-methylphenyl)urea,
Danirixin,
GSK1325756,
954126-98-8,
UNII-R318PGH5VP,
GSK-1325756B,
R318PGH5VP,
GSK1325756B,
Danirixin [USAN:INN],
GSK-1325756,
GSK 1325756,
Danirixin (USAN/INN),
Danirixin(GSK1325756),
GTPL8500,
SCHEMBL1198688,
CHEMBL3039531,
1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea,
EX-A1178,
ZINC95627831,
AKOS030527036,
CS-5465,
DB11922,
1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea,
HY-19768,
D10387,
(S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea,
D0R7XD,
1-[4-Chloro-2-hydroxy-3-(piperidine-3-sulfonyl)-phenyl]-3-(3-fluoro-2-methyl-phenyl)-urea,